Glucuretics: A New Class of Drug for the Treatment of Type 2 Diabetes

Authors

  • Md Azizul Hoque Assistant Professor, Department of Endocrinology, Sir Salimullah Medical College, Dhaka
  • SM Tajdit Rahman Intern Doctor, Sir Salimullah Medical College Mitford Hospital, Dhaka
  • Md Daharul Islam Assistant Professor, Department of Medicine, Sir Salimullah Medical College, Dhaka
  • Nazma Akter Resident Physician, MARKS Medical College Hospital, Dhaka

DOI:

https://doi.org/10.3329/kyamcj.v6i1.32789

Abstract

Type 2 diabetes is a common, chronic disease with a prevalence that is increasing at epidemic proportions. Management involves advice on lifestyle changes, oral anti-hyperglycaemic agents and/or insulin. The kidney plays an important role in glucose homeostasis via its production, utilization, and, most importantly, reabsorption of glucose from glomerular filtrate which is largely mediated via the sodium glucose cotransporter 2 (SGLT2). Competitive inhibition of SGLT2 induces glucosuria in a dose dependent manner and appears to have beneficial effects on glucose regulation in individuals with type 2 diabetes. Agents that inhibit SGLT2 represent a novel class of drugs, which has recently become available for treatment of type 2 diabetes. This article summarizes the rationale for use of these agents and reviews available clinical data on their efficacy, safety, and risks/benefits.

KYAMC Journal Vol. 6, No.-1, Jul 2015, Page 592-597

Downloads

Download data is not yet available.
Abstract
19
PDF
18

Author Biography

Md Azizul Hoque, Assistant Professor, Department of Endocrinology, Sir Salimullah Medical College, Dhaka



Downloads

Published

2017-06-04

How to Cite

Hoque, M. A., Rahman, S. T., Islam, M. D., & Akter, N. (2017). Glucuretics: A New Class of Drug for the Treatment of Type 2 Diabetes. KYAMC Journal, 6(1), 592–597. https://doi.org/10.3329/kyamcj.v6i1.32789

Issue

Vol. 6 No. 1 (2015)

Section

Review Articles